Benzoyl 2-methyl indoles as selective PPARgamma modulators

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Endocrinology

Background:

• Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose metabolism and insulin sensitivity.
• PPARγ agonists have shown therapeutic potential for type 2 diabetes but are limited by side effects.
• Selective PPARγ modulators (SPPARγMs) offer a potential strategy to improve the therapeutic window.

Purpose of the Study:

• To discover and develop novel PPARγ ligands with improved selectivity and efficacy.
• To synthesize and characterize a series of substituted 3-benzyl-2-methyl indoles as potential SPPARγMs.
• To evaluate the anti-diabetic activity and therapeutic window of a lead SPPARγM candidate in a preclinical model.

Main Methods:

• High-throughput screening for human PPARγ ligands.
• Structure-activity relationship (SAR) studies and synthetic modifications of initial hits.
• In vitro assays to determine PPARγ agonism and selectivity.
• In vivo efficacy studies in a rodent model of diabetes.

Main Results:

• Routine screening identified compounds 1 and 2 as sub-micromolar hPPARγ agonists.
• Synthetic efforts yielded potent substituted 3-benzyl-2-methyl indoles, with a subset identified as SPPARγMs.
• SPPARγM 24 exhibited robust anti-diabetic activity and a superior therapeutic window compared to a full PPARγ agonist in a rodent model.

Conclusions:

• Substituted 3-benzyl-2-methyl indoles represent a promising scaffold for developing SPPARγMs.
• SPPARγM 24 demonstrates significant potential as an anti-diabetic agent with an improved safety profile.
• Further investigation of SPPARγMs is warranted for the treatment of type 2 diabetes.